Oxford Biomedica PLC

Director's Dealing • Oct 12, 2022

National Storage Mechanism | Additional information

RNS Number : 5590C

Oxford Biomedica PLC

12 October 2022

PDMR Dealings

Oxford, UK - 12 October 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE:OXB), was informed on 11 October 2022, that Tim Kelly, Chief Executive Officer of Oxford Biomedica Solutions, exercised 14,690 RSU (2022) options at nil cost on 10 October 2022, and sold all the resulting ordinary shares at 315p per share on 11 October 2022. Following this transaction, Tim Kelly continues to hold 176,615 options over ordinary shares. 

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of ordinary shares exercised and then sold.

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")

a)

Name

Tim Kelly  

2.

Reason for the notification

a)

Position/status

Chief Executive Officer of Oxford Biomedica Solutions

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Options over ordinary shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Exercise of options

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

Price(s)	Volume(s)
Nil	14,690

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

14,690

Nil

f)

Date of the transaction

2022-10-10

g)

Place of the transaction

Outside a trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")

a)

Name

Tim Kelly

2.

Reason for the notification

a)

Position/status

Chief Executive Officer of Oxford Biomedica Solutions

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Sale of ordinary shares

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

Price(s)	Volume(s)
£3.15	14,690

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

14,690

£46,273.50

f)

Date of the transaction

2022-10-11

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: +44 (0)1865 783 000

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Further information is available at www.oxb.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFFUESFEESEFS